Clarke, Modet & Cº
COLOMBIA

ESCOBAR - URIBE ASOCIADOS
Intellectual Property

As. 3001/PCT.

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
DIVISIÓN DE NUEVAS CREACIONES
E. S. D.

Ref.: Expediente No. **06.097.280**
Solicitud de Patente a nombre de
JANSSEN PHARMACEUTICA N.V.

Yo, **JIMENA ESCOBAR URIBE**, identificada como aparece al pie de mi firma, domiciliada en Bogotá, en la Carrera 11 No. 86-53, piso 6, obrando como apoderada de la sociedad **JANSSEN PHARMACEUTICA N.V.,** con domicilio en Beerse, Bélgica, solicitante de la patente de la referencia, doy alcance al memorial presentado el 19 de agosto de 2008 y pido a usted que se proceda a examinar si la invención, cuya patente se tramita en el expediente de la referencia, es patentable.

Adjunto al presente memorial el recibo Nr. 08-59,263 de 23 de julio de 2008, por la suma de $210.000.oo, como pago del excedente de la tasa oficial correspondiente a dicho estudio.

Señor Superintendente,

JIMENA ESCOBAR URIBE
C.C.39.779.452 de Usaquén
T.P. 68.228

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 900176089-2

RECIBO OFICIAL DE CAJA : 08 - 59,263
FECHA : JULIO 23 DE 2008

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
No. 06-097280- -00006-0000
Fecha: 2008-08-20 14:54:48 Dep: 2020 NUEVAS SOLICITUDES
Tra: 11 PATENTES Y II Liq: 378 FASE NACIONAL
Act: 330 COMUNICACIÓN Folios: 5

***** C O N S I G N A C I O N *****

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PGO	Vr. PAGO
CLARKE MODET Y CO. COLOMB	CONSIGNACION	BANCO DE BOGOTA	062754387	693136	23/07/2008	50,740,000.00

***** C O N C E P T O *****

CANT.	RENTISTICO	CONCEPTO		TOTAL CONCEPTO
1	50005-01-01 SOLICITUDES	114	PTC CAP-II EXAMEN DE PATENTIBILID	210,000.00
			TOTAL : $	210,000.00

SON: DOSCIENTOS DIEZ MIL PESOS

RESPONSABLE : _____

RECIBO DE CAJA APLICADO AL EXPEDIENTE No. _____

Clarke, Modet & Cº
COLOMBIA

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
No. 06-097280- -00005-0000
Fecha: 2008-08-19 14:40:12 Dep: 2020 NUECREACIONE
Tra: 11 PATENTEIYII Eve: 378 FASENACIONALI
Act: 330 COMUNICACIÓN Folios: 3

As. 3001/PCT.

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
DIVISIÓN DE NUEVAS CREACIONES
E. S. D.

Ref.: Expediente No. **06.097.280**
Solicitud de Patente a nombre de
JANSSEN PHARMACEUTICA N.V.

Yo, **JIMENA ESCOBAR URIBE**, identificada como aparece al pie de mi firma, domiciliada en Bogotá, en la Carrera 11 No. 86-53, piso 6, obrando como apoderada de la sociedad **JANSSEN PHARMACEUTICA N.V.,** con domicilio en Beerse, Bélgica, solicitante de la patente de la referencia, pido a usted que se proceda a examinar si la invención, cuya patente se tramita en el expediente de la referencia, es patentable.

Adjunto al presente memorial el recibo Nr. 08-59,262 de 23 de julio de 2008, por la suma de $210.000.oo, con lo cual queda cubierta la tasa oficial correspondiente a dicho estudio.

Señor Superintendente,

JIMENA ESCOBAR URIBE
C.C.39.779.452 de Usaquén
T.P. 68.228

Industria y Comercio
SUPERINTENDENCIA

DIVISIÓN DE NUEVAS CREACIONES

RADICACIÓN EXPEDIENTE No. 06-97280

EL EXTRACTO DE LA PRESENTE SOLICITUD DE **PATENTE DE INVENCIÓN**

FUE PUBLICADO EN LA GACETA DE PROPIEDAD INDUSTRIAL No **589** DE

FECHA **29 DE FEBRERO DE 2008** EL TÉRMINO HÁBIL SEÑALADO POR LA

LEY EXPIRA EL **03 DE JUNIO DE 2008**

NOTA: Dentro del plazo de los seis (6) meses siguientes a partir de la fecha de publicación en la gaceta de Propiedad Industrial, deberá solicitar y cancelar el examen de patentabilidad so pena de que la solicitud caiga en abandono, de acuerdo con lo establecido en el Artículo 44 de la Decisión 486/2000.

SE PRESENTARON OPOSICIONES POR PARTE DE TERCEROS.

SI _____ NO ____X____

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 May 2003 (01.05.2003)

PCT

(10) International Publication Number
WO 03/035005 A2

(51) International Patent Classification[7]: A61K

(21) International Application Number: PCT/US02/34395

(22) International Filing Date: 28 October 2002 (28.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/348,869 26 October 2001 (26.10.2001) US

(71) Applicant *(for all designated States except US)*: **UNIVERSITY OF CONNECTICUT** [US/US]; 263 Farmington Avenue, Farmington, CT 06030-6207 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **MAKRIYANNIS, Alexandros** [US/US]; 3 Thomas Street, Mystic, CT 06355 (US). **LIU, Qian** [CN/US]; 1 Northwood Road, Apt. #25, Storrs, CT 06268 (US).

(74) Agents: **YALE, Guy, D.** et al.; Alix, Yale & Ristas, LLP, 750 Main Street, Suite 1400, Hartford, CT 06103-2721 (US).

(81) Designated States *(national)*: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
- *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/035005 A2

(54) Title: HETEROINDANES: A NEW CLASS OF POTENT CANNABIMIMETIC LIGANDS

(57) Abstract: One aspect of the invention is concerned with cannabimimetic heteroindane analogs having affinities and/or selectivities for a cannabinoid receptor. A further aspect of the invention is concerned with pharmaceutical preparations employing the inventive analogs and methods of administering therapeutically effective amounts of the inventive analogs to provide a physiological effect.

What Is Claimed Is:

1. A compound of formula I below, and physiologically acceptable salts, comprising:



wherein,

R1 comprises –Q–Z;

Q comprises an optionally present alkyl group having 1 to about 7 carbon atoms if present;

Z comprises, in any possible position, any possible member selected from H, halogen, N_3, NCS, CN, NO_2, NX_1X_2, OX_3, OAc, NHCOalkyl, CHO, CF_3, $C(O)OX_3$, SO_3H, $SO_2NX_1X_2$, $CONX_1X_2$, acyl, substituted acyl, aroyl, substituted aroyl, heteroaroyl, substituted heteroaroyl, O-acyl, O-aroyl, OalkylOH, $OalkylNX_1X_2$, NH-acyl, NH-aroyl, alkoxy, alkylmercapto, alkylamino or di-alkylamino;

X_1 and X_2 each independently comprise H or alkyl, or

X_1 and X_2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from O, N or S, or

X_1 and X_2 together comprise part of an imide ring having about 5 to about 6 members,

X_3 comprises H, alkyl, hydroxyloweralkyl, or alkyl-NX_1X_2; or

Z comprises, in any possible position, any possible member selected from 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group independently substituted on at least one available ring nitrogen atom by at least one of an alkyl group, a benzyl group, a lower-alkoxybenzyl group, a benzhydryl group, a substituted benzhydryl group, a phenyl group, a substituted phenyl group, a methylbenzyl group, a substituted methylbenzyl group; or any above

group substituted on at least one available ring carbon atom by an alkyl group and independently substituted on at least one available ring nitrogen atom by at least one of an alkyl group, a benzyl group, a lower-alkoxybenzyl group, a benzhydryl group, a substituted benzhydryl group, a phenyl group, a substituted phenyl group, a methylbenzyl group, a substituted methylbenzyl group; and wherein the connecting point to the Z group can be any possible ring atom; or

Z comprises, in any possible position, any possible member selected from a carbocyclic ring having about 4 to about 7 ring members, a heterocyclic ring having about 4 to about 7 ring members, an aromatic ring having about 5 to about 7 ring members, a heteroaromatic ring having about 5 to about 7 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group comprising a substituent group on at least one available ring atom; and wherein the connecting point to the Z group can be any possible ring atom; or

Z comprises, in any possible position, any possible member selected from



wherein X and Y in the Z structure each independently comprise H, halogen, N_3, NCS, CN, NO_2, NX_1X_2, OX_3, OAc, NHCOalkyl, CHO, CF_3, $C(O)OX_3$, SO_3H, $SO_2NX_1X_2$, $CONX_1X_2$, acyl, substituted acyl, aroyl, substituted aroyl, heteroaroyl, substituted heteroaroyl, O-acyl, O-aroyl, OalkylOH, $OalkylNX_1X_2$, NH-acyl, NH-aroyl, alkoxy, alkylmercapto, alkylamino or di-alkylamino, alkylsulfinyl, alkylsulfonyl or methylene dioxy when Z comprises a structure having two adjacent carbon atoms,

X_1 and X_2 each independently comprise H or alkyl, or

X_1 and X_2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from O, N or S, or

X_1 and X_2 together comprise part of an imide ring having about 5 to about 6 members.

X_3 comprises H, alkyl, hydroxyloweralkyl, or alkyl-NX_1X_2;

R2 comprises $-Q_1-het-Q_2-Z$;

Q_1 comprises an optionally present alkyl group having 1 to about 5 carbon atoms if present;

het comprises O, N or S;

Q_2 comprises an optionally present alkyl group having 1 to about 5 carbon atoms if present;

Z comprises, in any possible position, any possible member selected from H, halogen, N_3, NCS, CN, NO_2, NX_1X_2, OX_3, OAc, NHCOalkyl, CHO, CF_3, $C(O)OX_3$, SO_3H, $SO_2NX_1X_2$, $CONX_1X_2$, acyl, substituted acyl, aroyl, substituted aroyl, heteroaroyl, substituted heteroaroyl, O-acyl, O-aroyl, OalkylOH, $OalkylNX_1X_2$, NH-acyl, NH-aroyl, alkoxy, alkylmercapto, alkylamino or di-alkylamino.

X_1 and X_2 each independently comprise H or alkyl, or

X_1 and X_2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from O, N or S, or

X_1 and X_2 together comprise part of an imide ring having about 5 to about 6 members.

X_3 comprises H, alkyl, hydroxyloweralkyl, or alkyl-NX_1X_2; or

Z comprises, in any possible position, any possible member selected from 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group independently substituted on at least one available ring nitrogen atom by at least one of an alkyl group, a benzyl group, a lower-alkoxybenzyl group,

a benzhydryl group, a substituted benzhydryl group, a phenyl group, a substituted phenyl group, a methylbenzyl group, a substituted methylbenzyl group; or any above group substituted on at least one available ring carbon atom by an alkyl group and independently substituted on at least one available ring nitrogen atom by at least one of an alkyl group, a benzyl group, a lower-alkoxybenzyl group, a benzhydryl group, a substituted benzhydryl group, a phenyl group, a substituted phenyl group, a methylbenzyl group, a substituted methylbenzyl group; and wherein the connecting point to the Z group can be any possible ring atom; or

Z comprises, in any possible position, any possible member selected from



wherein X and Y in the Z structure each independently comprise H, halogen, N_3, NCS, CN, NO_2, NX_1X_2, OX_3, OAc, NHCOalkyl, CHO, CF_3, $C(O)OX_3$, SO_3H, $SO_2NX_1X_2$, $CONX_1X_2$, acyl, substituted acyl, aroyl, substituted aroyl, heteroaroyl, substituted heteroaroyl, O-acyl, O-aroyl, OalkylOH, $OalkylNX_1X_2$, NH-acyl, NH-aroyl, alkoxy, alkylmercapto, alkylamino or di-alkylamino, alkylsulfinyl, alkylsulfonyl or methylene dioxy when Z comprises a structure having two adjacent carbon atoms,

X_1 and X_2 each independently comprise H or alkyl, or

X_1 and X_2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from O, N or S, or

X_1 and X_2 together comprise part of an imide ring having about 5 to about 6 members,

X_3 comprises H, alkyl, hydroxyloweralkyl, or alkyl-NX_1X_2; or

Z comprises, in any possible position, any possible member selected from a carbocyclic ring having about 4 to about 7 ring members, a heterocyclic ring having about 4 to about 7 ring members, an aromatic ring having about 5 to about 7 ring members, a heteroaromatic ring having about 5 to about 7 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom; and wherein the connecting point to the Z group can be any possible ring atom; or

R2 comprises $-Q_1-X-Q_2-Z$;

Q_1 comprises an optionally present alkyl group having 1 to about 5 carbon atoms if present;

Q_2 comprises an optionally present alkyl group having 1 to about 5 carbon atoms if present and connected to a C, O or N atom in the X group;

X is optionally present and comprises any possible member selected from C(O), C(O)O, OC(O)O, NC(O)O, C(O)NT, NTC(O), OC(O)NT, C(O)NTT, C(O)NTNT, NTC(O)NT if present,

T comprises H, an alkyl group comprising 1 to about 4 C atoms, a heteroalkyl group comprising 1 to about 4 C atoms, a carbocyclic ring having about 4 to about 7 ring members, a heterocyclic ring having about 4 to about 7 ring members, an aromatic ring having about 5 to about 7 ring members or a heteroaromatic ring having about 5 to about 7 ring members or any above group having a substituent group on at least one available ring atom;

Z comprises in any possible position, any possible member selected from H, halogen, N_3, NCS, CN, NO_2, NX_1X_2, OX_3, OAc, NHCOalkyl, CHO, CF_3, $C(O)OX_3$, SO_3H, $SO_2NX_1X_2$, $CONX_1X_2$, acyl, substituted acyl, aroyl, substituted aroyl, heteroaroyl, substituted heteroaroyl, O-acyl, O-aroyl, OalkylOH, OalkylNX_1X_2, NH-acyl, NH-aroyl, alkoxy, alkylmercapto, alkylamino or di-alkylamino,

X_1 and X_2 each independently comprise H or alkyl, or

X_1 and X_2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from O, N or S, or

X_1 and X_2 together comprise part of an imide ring having about 5 to about 6 members,

X_3 comprises H, alkyl, hydroxyloweralkyl, or alkyl-NX_1X_2; or

Z comprises, in any possible position, any possible member selected from 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group independently substituted on at least one available ring nitrogen atom by at least one of an alkyl group, a benzyl group, a lower-alkoxybenzyl group, a benzhydryl group, a substituted benzhydryl group, a phenyl group, a substituted phenyl group, a methylbenzyl group, a substituted methylbenzyl group; or any above group substituted on at least one available ring carbon atom by an alkyl group and independently substituted on at least one available ring nitrogen atom by at least one of an alkyl group, a benzyl group, a lower-alkoxybenzyl group, a benzhydryl group, a substituted benzhydryl group, a phenyl group, a substituted phenyl group, a methylbenzyl group, a substituted methylbenzyl group; and wherein the connecting point to the Z group can be any possible ring atom; or

Z comprises, in any possible position, any possible member selected from



wherein X and Y in the Z structure each independently comprise H, halogen, N_3, NCS, CN, NO_2, NX_1X_2, OX_3, OAc, NHCOalkyl, CHO, CF_3, $COOX_3$, SO_3H, $SO_2NX_1X_2$, $CONX_1X_2$, acyl, substituted acyl, aroyl, substituted aroyl, heteroaroyl, substituted heteroaroyl, O-acyl, O-aroyl, OalkylOH, $OalkylNX_1X_2$, NH-acyl, NH-aroyl, alkoxy, alkylmercapto, alkylamino or di-alkylamino, alkylsulfinyl, alkylsulfonyl or methylene dioxy when Z comprises a structure having two adjacent carbon atoms,

X_1 and X_2 each independently comprise H or alkyl, or

X_1 and X_2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from O, N or S, or

X_1 and X_2 together comprise part of an imide ring having about 5 to about 6 members,

X_3 comprises H, alkyl, hydroxyloweralkyl, or alkyl-NX_1X_2; or

Z comprises, in any possible position, any possible member selected from a carbocyclic ring having about 4 to about 7 ring members, a heterocyclic ring having about 4 to about 7 ring members, an aromatic ring having about 5 to about 7 ring members, a heteroaromatic ring having about 5 to about 7 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group comprising a substituent group on at least one available ring atom; and wherein the connecting point to the Z group can be any possible ring atom; and

R3 comprises a substituent at any or all of the possible 4–, 5–, 6– and/or 7–positions, wherein each substituent is independently selected from H, halogen, N_3, NCS, CN, NO_2, NX_1X_2, OX_3, OAc, NHCOalkyl, CHO, CF_3, $COOX_3$, SO_3H, $SO_2NX_1X_2$, $CONX_1X_2$, acyl, substituted acyl, aroyl, substituted aroyl, heteroaroyl, substituted heteroaroyl, O-acyl, O-aroyl, OalkylOH, $OalkylNX_1X_2$, NH-acyl, NH-aroyl, alkoxy, alkylmercapto, alkylamino or di-alkylamino, alkylsulfinyl, alkylsulfonyl or methylene dioxy when Z comprises a structure having two adjacent carbon atoms,

X_1 and X_2 each independently comprise H or alkyl, or

X_1 and X_2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from O, N or S, or

X_1 and X_2 together comprise part of an imide ring having about 5 to about 6 members,

X_3 comprises H, alkyl, hydroxyloweralkyl, or alkyl-NX_1X_2.

2. The compound of claim 1 wherein R1 comprises -Q-Z; Q comprises an optionally present alkyl group having 1 to about 7 carbon atoms if present; and Z comprises adamantyl or heteroadamantyl.

3. The compound of claim 1 wherein R2 comprises $-Q_1-het-Q_2-Z$; and Z comprises adamantyl or heteroadamantyl.

4. The compound of claim 1 wherein R2 comprises $-Q_1-X-Q_2-Z$ and Q_1 comprises an alkyl group having 1 to about 5 carbon atoms if X is CO.

5. The compound of claim 1 wherein R2 comprises $-Q_1-X-Q_2-Z$; and Z comprises adamantyl or heteroadamantyl.

6. The compound of claim 1 wherein R2 comprises $-Q_1-X-Q_2-Z$; and Z comprises phenyl having independently selected substituent groups in at least one of the 2 and 5 positions.

7. The compound of claim 1 wherein R2 comprises $-Q_1-X-Q_2-Z$; and Z comprises phenyl substituted with a heteroaromatic moiety.

8. The compound of claim 1 wherein R2 comprises $-Q_1-X-Q_2-Z$; and Z comprises phenyl substituted in one of the 2 or 5 position with a heteroaromatic moiety and in the other of the 2 or 5 position with a halogen.

283

~~283~~

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
DIRECCIÓN DE NUEVAS CREACIONES

2020
Bogotá, D.C.,

Abogada
JIMENA ESCOBAR URIBE
Apoderada

ASUNTO	Radicación	06-097280
	Trámite	011
	Evento	379
	Actuación	430
	Oficio	
	Folios	286

Patente de Invención	■	Patente de Modelo de Utilidad		☐
Vía Nacional	☐			
Vía PCT (fase nacional)	■	Cap.I	☐	Cap. II ■

No. Sol. Internacional PCT/US2005/009819
Fecha de Presentación Internal. 2005/03/23

Como resultado del examen de fondo, realizado con fundamento en el artículo 45 de la Decisión 486 de la Comisión de la Comunidad Andina, se le comunica:

1. Documentos estudiados

Descripción: Folios: 8 a 215

Reivindicaciones: Folios 216 a 227

Prioridad: Fecha: 2004/03/24, país: US, número: 60/555.890

2. Objeto de la invención

- Título de la solicitud: Moduladores canabinoides de tetrahidro-indazol. número de folio: 1.

El problema planteado en esta solicitud es la necesidad de compuestos útiles en los síndromes mediados por el receptor canabinoide.

Para solucionar este problema técnico la solicitud en estudio proporciona compuestos tetrahidro-indazol moduladores canabinoides (CB).

Clasificación Internacional de Patentes (IPC.): C07D 231/56

3. De la solicitud de Patente

Reivindicaciones *(artículo 30 D 486)*

Una vez revisado el capitulo reivindicatorio esta dependencia encuentra:

- Se requiere al solicitante delimitar la materia reivindicada en cuanto a los sustituyentes **arilo, alquileno inferior, alquilideno inferior, alquilo inferior, heteroarilo, cicloalquilo** ya que no se está determinando su ***tamaño*** lo cual implica que se usan de forma especulativa como términos genéricos que no definen inequívocamente una estructura específica.
- El solicitante no es claro cuando incluye en sus reivindicaciones los compuestos: ***"profármaco" o "isómero" o "metabolito" o "polimorfo"***. Al realizar la lectura del capítulo reivindicatorio, se encuentra que las frases resultan imprecisas, dado que no especifican con exactitud el(los) compuesto(s) a los cuales se refiere con dichos términos por lo tanto no se aceptan tal como aparecen.

El objeto de la solicitud no es claro e incumple así mismo con el requisito de concisión, dadas las observaciones esbozadas en los numerales precedentes. En este sentido se requiere al interesado para que realice las modificaciones correspondientes a fin de subsanar las no conformidades encontradas por este Despacho.

4. Excepción a la patentabilidad *(artículo 20 D486 literal a)-d)*

Reivindicaciones 18 - 28: Se refiere a un método para tratar una enfermedad mediada por el receptor canabinoide por lo tanto están exceptuadas de patentabilidad según la legislación vigente.

5. Determinación del Estado de la Técnica

La fecha que se ha tenido en cuenta para determinar el Estado de la Técnica es:

Fecha de presentación de la solicitud prioritaria 2004/03/24

Teniendo en cuenta la fecha indicada se realizó la búsqueda en el estado de la técnica de documentos relacionados con la solicitud encontrándose los siguientes documentos más relevantes:

Nº	Documento	Título	Fecha de publicación*
D_1	WO 03/035005	HETEROINDANES: A NEW CLASS OF POTENT CANNABIMIMETIC LIGANDS	2003/05/1

6. Análisis de patentabilidad (artículo 14 D486)

Novedad (artículo 16 D486)

Reivindicaciones 1 - 17: compuestos de la fórmula general (I).



D1 enseña análogos heteroindanos canabimiméticos con afinidades y/o selectividades por el receptor canabinoide. (pag 274)

- Los elementos característicos de la composición de la reivindicación 1, habían sido divulgados previamente en el Estado de la Técnica según la tabla siguiente:

TABLA 1

SOLICITUD		ANTERIORIDAD (D_1)		Comparación
				
X_1 R_1	X_1 = no está R_1 = Arilo sustituido com halogeno, alquilo, hidroxi, alcoxi	R_1	Q-Z Q= no está presente Z= Arilo sustituido	IGUAL
X_2 R_2	No está cuando está presente			IGUAL
	H	R_3	H	IGUAL
X_3 R_3	 Donde: R_6 = -CH(R_{6a}) = H, alquilo Z_1= ausente R_7 = alquilo opcionalmente sustituido	R_2	Q_1-het_1-Q_2-Z Donde: Q_1= alquilo Het_1 = O Q_2 = alquilo Z = H, halógeno, N_3, NCS, NO_2, NH_2	IGUAL
X_4 R_4	ausente			